Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

PURPOSE: The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer (NSCLC) has not been clarified. A pooled analysis of prospective clinical trials was conducted to evaluate the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Li, Guo, Yi-Jia, Song, Jun, Wang, Yan-Ru, Zhang, Shu-Ling, Huang, Le-Tian, Zhao, Jian-Zhu, Jing, Wei, Han, Cheng-Bo, Ma, Jie-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837071/
https://www.ncbi.nlm.nih.gov/pubmed/33511076
http://dx.doi.org/10.3389/fonc.2020.586596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837071/
https://www.ncbi.nlm.nih.gov/pubmed/33511076
http://dx.doi.org/10.3389/fonc.2020.586596

Ejemplares similares